Research suggests that female patients with newly diagnosed heart failure with reduced ejection fraction may be less likely to receive guideline-directed medical therapies than male patients. The use and intensification of these therapies appears to be lower in women, although the extent of these disparities is not fully clear. Studies are highlighting the need for increased awareness and efforts to address gaps in treatment and risk factor control for heart failure and related conditions.